The companies determined to address the planet’s deadliest diseases


These healthcare firms are looking to make their mark by developing treatments for some of the planet’s nastiest diseases and health conditions.

Doctor consulting with patient

Some of the most prevalent health conditions on the planet claim millions of lives every year. Companies from across the healthcare sector are constantly innovating to try to combat these illnesses, pushing hard to find breakthrough cures and quality of life improvements. In today’s article, this issue is discussed with reference to Verona Pharma (NASDAQ: VRNA), Insulet Corporation (NASDAQ: PODD), Novartis (NYSE: NVS) and Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL.TO).

Cardiovascular diseases are the biggest cause of death today, with more than 800,000 Americans suffering from heart attacks every year according to the Centers for Disease Control and Prevention (CDC). Meanwhile, CDC data from 2018 indicated that more than 30 million Americans were living with heart disease.

Cardiol Therapeutics (NASDAQ: CRDL) (TSX: CRDL.TO) aims to develop treatments to help people live more comfortably with heart conditions. Their primary focus of interest is on treatments for acute myocarditis, recurrent pericarditis, and diastolic heart failure.

The company is currently researching and developing an anti-inflammatory and anti-fibrotic therapy for the treatment of cardiovascular diseases. Its lead product candidate, CardiolRx™, is a pharmaceutically produced oral formulation being clinically designed for use in cardiovascular medicine.

Most recently, Cardiol Therapeutics announced that it had received authorization from the US Food and Drug Administration (FDA) to begin a trial examining the tolerance and safety of CardiolRx™ in patients suffering from recurrent pericarditis.

This condition, along with acute myocarditis, are classed as an orphan disease in the United States, making CardiolRx™ eligible for orphan drug status under the FDA’s Orphan Drug Designation program. This program brings benefits such as fee exemptions and even the potential for seven years of market exclusivity following a drug’s approval.

Cardiol Therapeutics’ Chief Medical Officer, Dr Andrew Hamer, commented:

“With Investigational New Drug authorization now in place, we look forward to ramping up initiation of this important study. We also anticipate benefiting from the clinical trial infrastructure already established for our multi-national acute myocarditis study, which is expected to commence patient enrollment imminently.”

While cardiovascular diseases might be the planet’s leading cause of death, respiratory diseases are also a huge issue. Among the companies developing treatments in this space is Verona Pharma (NASDAQ: VRNA), which is developing drugs to combat chronic obstructive pulmonary disease (COPD).

COPD is a group of lung conditions that can cause sufferers great difficulties with breathing due to factors such as lung damage and inflammation of the airways. They generally affect people over the age of 35 and are particularly prevalent in individuals who smoke or used to smoke.

According to Verona, 384 million people around the world suffer from COPD, with the condition constituting the planet’s third most prevalent cause of death. As such, there is significant demand for treatments, with the company estimating that global sales of COPD drugs amounted to $13.6bn in 2019.

The company’s current projects include Ensifentrine, which is intended as a treatment for COPD and other respiratory diseases, such as asthma and cystic fibrosis. It has anti-inflammatory properties and functions as a bronchodilator, improving patients’ breathing by relaxing muscles in the lungs and widening airways.

Positive results have been achieved in trials involving more than 1,400 patients and Verona Pharma has also indicated that the drug could be an effective treatment for cystic fibrosis.

Diabetes is another huge health problem for humanity. The World Health Organization says that more than 420 million people across the globe have diabetes, with more than 1.5 million people dying from the condition each year.

Insulet Corporation (NASDAQ: PODD) is a Massachusetts-based medical equipment business that is seeking to provide simpler insulin delivery methods for people who live with diabetes.

The company’s Omnipod Insulin Management System offers pump delivery rather than multiple daily injections. According to Insulet, this means improved glycaemic control, fewer hypoglycaemic events, reduced glycaemic variability and a better quality of life for patients.

Indeed, in early June the company announced that a recent study had found that 12 months of use of its pump technology resulted in significantly improved glycaemic outcomes for children between the ages of 2 and 6.

Insulet added that clinical data showed that its Omnipod 5 technology resulted in improved outcomes for adults and children who lived with Type 1 diabetes, as well as adults dealing with Type 2 diabetes.

In addition to these applications in relation to diabetes, the company says it leverages the technology behind Omnipod to allow for the delivery of non-insulin subcutaneous drugs, creating additional applications across alternative therapeutic areas.

Cancer is another monumental healthcare challenge. Figures provided by the World Cancer Research Fund International put the total number of estimated new cancer cases in 2020 at more than 18 million. What’s more, the National Cancer Institute puts the cancer death rate at 158.3 per 100,000 men and women per year.

Novartis (NYSE: NVS) is a company that has found success recently in pushing for approval with cancer treatments.

In late June the company received FDA approval for its Tafinlar® (dabrafenib) + Mekinist® (trametinib) treatments in some adult and pediatric patients 6 years of age and older who have no alternative treatment options for their unresectable or metastatic solid tumors.

While this is something of a niche approval, the company will be hoping that the treatment will achieve some success in these seriously ill patients and see its approval expanded.

Novartis Oncology US Head, Reshema Kemps-Polanco, commented:

“Tackling cancer is complex, which is why it is so important that we continue to follow the science as we pursue meaningful advances and new approaches to treating cancer. We are grateful to the patients, and to the multitude of individuals and teams working together to make this latest approval possible as we strive to do more for more people living with cancer.”

This combined treatment is just one facet of Novartis’ expansive set of oncology products, which includes more than 20 different medications developed to improve the lives of patients.




This communication is a paid advertisement. ValueTheMarkets is a trading name of Digitonic Ltd, and its owners, directors, officers, employees, affiliates, agents and assigns (collectively the “Publisher”) is often paid by one or more of the profiled companies or a third party to disseminate these types of communications. In this case, the Publisher has been compensated by Cardiol Therapeutics Inc to conduct investor awareness advertising and marketing and has paid the Publisher the equivalent of One Hundred and Eighty Thousand Dollars to produce and disseminate this and other similar articles and certain related banner advertisements. This compensation should be viewed as a major conflict with the Publisher’s ability to provide unbiased information or opinion.


Readers should beware that third parties, profiled companies, and/or their affiliates may liquidate shares of the profiled companies at any time, including at or near the time you receive this communication, which has the potential to adversely affect share prices. Frequently companies profiled in our articles experience a large increase in share trading volume and share price during the course of investor awareness marketing, which often ends as soon as the investor awareness marketing ceases. The investor awareness marketing may be as brief as one day, after which a large decrease in share trading volume and share price may likely occur.


This communication is not, and should not be construed to be, an offer to sell or a solicitation of an offer to buy any security.


Neither this communication nor the Publisher purport to provide a complete analysis of any company or its financial position.

This communication is based on information generally available to the public and on an interview conducted with the company’s CEO, and does not contain any material, non-public information. The information on which it is based is believed to be reliable. Nevertheless, the Publisher does not guarantee the accuracy or completeness of the information. Further, the information in this communication is not updated after publication and may become inaccurate or outdated. No reliance should be placed on the price or statistics information and no responsibility or liability is accepted for any error or inaccuracy. Any statements made should not be taken as an endorsement of analyst views.


The Publisher is not, and does not purport to be, a broker-dealer or registered investment adviser or a financial adviser. The Publisher has no access to non-public information about publicly traded companies. The information provided is general and impersonal, and is not tailored to any particular individual’s financial situation or investment objective(s) and this communication is not, and should not be construed to be, personalized investment advice directed to or appropriate for any particular investor or a personal recommendation to deal or invest in any particular company or product. Any investment should be made only after consulting a professional investment advisor and only after reviewing the financial statements and other pertinent corporate information about the company. Further, readers are advised to read and carefully consider the Risk Factors identified and discussed in the advertised company’s SEC, SEDAR and/or other government filings. Investing in securities, particularly microcap securities, is speculative and carries a high degree of risk. Past performance does not guarantee future results.


This communication contains forward-looking statements, including statements regarding expected continual growth of the featured companies and/or industry. Statements in this communication that look forward in time, which include everything other than historical information, are based on assumptions and estimates by our content providers and involve risks and uncertainties that may affect the profiled company’s actual results of operations. These statements involve known and unknown risks, uncertainties and other important factors that could cause the actual results and performance to differ materially from any future results or performance expressed or implied in the forward-looking statements. These risks, uncertainties and other factors include, among others: the success of the profiled company’s operations; the size and growth of the market for the company’s products and services; the company’s ability to fund its capital requirements in the near term and long term; pricing pressures; changes in business strategy, practices or customer relationships; general worldwide economic and business conditions; currency exchange and interest rate fluctuations; government, statutory, regulatory or administrative initiatives affecting the company’s business.


By reading this communication, you acknowledge that you have read and understand this disclaimer in full, and agree and accept that the Publisher provides no warranty in respect of the communication or the profiled company and accepts no liability whatsoever. You acknowledge and accept this disclaimer and that, to the greatest extent permitted under applicable law, you release and hold harmless the Publisher from any and all liability, damages, injury and adverse consequences arising from your use of this communication. You further agree that you are solely responsible for any financial outcome related to or arising from your investment decisions.


By reading this communication you agree that you have reviewed and fully agree to the Terms of Use found here and acknowledge that you have reviewed the Disclaimer found here If you do not agree to the Terms of Use, please contact to discontinue receiving future communications.


All trademarks used in this communication are the property of their respective trademark holders. Other than, the Publisher is not affiliated, connected, or associated with, and the communication is not sponsored, approved, or originated by, the trademark holders unless otherwise stated. No claim is made by the Publisher to any rights in any third-party trademarks other than

AUTHORS: VALUETHEMARKETS and Digitonic Ltd and our affiliates are not responsible for the content or accuracy of this article. The information included in this article is based solely on information provided by the company or companies mentioned above. This article does not provide any financial advice and is not a recommendation to deal in any securities or product. News and research are not recommendations to deal, and investments may fall in value so that you could lose some or all of your investment. Past performance is not an indicator of future performance.

ValueTheMarkets do not hold any position in the stock(s) and/or financial instrument(s) mentioned in the above piece. ValueTheMarkets have been paid to produce this piece by the company or companies mentioned above. Digitonic Ltd, the owner of, has been paid for the production of this piece by the company or companies mentioned above.

Sign up for Investing Intel Newsletter